IBB News and Press, iShares Biotechnology ETF From 02/28/23

Summary Horizon Therapeutics Public Limited Company is a $25 billion biotech that's being acquired by Amgen Inc. The FTC has issued a 2nd request following a letter by Senator Elizabeth Warren. Warren raises a number of important issues but few that pertain specifically to this deal...

Summary We think value stocks can outperform as interest rates head higher. Regions and sectors help us find quality within value and growth at a reasonable price. Stocks slid after the Federal Reserve’s preferred inflation gauge showed persistently high inflation, reinforcing wh...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...

Summary Valneva SE is a French biotechnology company specializing in developing and commercializing vaccines. We expect approval of two attractive vaccine candidates targeting Chikungunya and Lyme disease by 2024-2025. The company has a relatively cheap valuation, enterprise value o...

Summary Bristol-Myers Squibb's revenue was $11,406 million in Q4 2022, showing mixed results compared to previous quarters, and there are many explanations for this, which will be discussed in the article. In 2023, the company's investors should receive a dividend of $2.28 per share, up...

Summary Lyell Immunopharma is a US biotechnology developer of innovative therapies for various types of cancer. Shares are falling in trend and headwinds could continue due to lost glamour for the portfolio. LYEL stock should not earn much more than a Sell rating. But when there's n...

Summary The private domestic sector balance decreased by -$52+ billion in January 2023. Bank credit retraction was -$41+ billion as more loans were repaid or written off than were created. The seasonal pattern is downwards now into March 2023 and probably into Xmas 2023 as well...

Summary Erasca, Inc. is a clinical-stage biopharmaceutical developer of therapies for patients with RAS/MAPK pathway-driven cancers. Shares were dragged down sharply by headwinds from the Fed's hawkish stance and other macroeconomic issues. Erasca has some positive catalysts that co...

Summary We initiate Xenon Pharmaceuticals with a BUY rating. We see XENE as one of the most de-risked and compelling SMID-cap biotech companies with a lead late-stage clinical candidate. We build a high degree of conviction based on recent phase 2b X-TOLE data that demonstrated a si...

Summary Omeros Corporation's stock has rallied 66% on Feb 6th based on the milestone payment of $200M, which eliminated the potential cash runway overhang some investors were worried about. With the additional $200M cash, now the enterprise value of the company is around $115M, which we...